Liquidia Gains FDA Fast Track For YUTREPIA In Raynaud's Linked To Systemic Sclerosis

Liquidia Corporation said the U.S. FDA granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). The Fast Track status is a supportive regulatory milestone that can accelerate development and review, which is likely to be viewed positively by investors.